维普中文期刊产品整合服务

Randomized,multicenter,open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer:NCT01631357

查看全文 作　　者：Liang [1]Liu;Quanli [2]Gao;Jingting [3]Jiang;Junping [4]Zhang;Xin [5]Song;Jiuwei [6]Cui;Yunbin [7]Ye;Zhiyu [8]Wang;Xinwei [1]Zhang;Xiubao [1]Ren 高影响力作者 机构地区：[1]Department of Immunology and Biotherapy,Key Laboratory of Cancer Immunology and Biotherapy,Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;[2]Department of Immunotherapy,Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou 450008 Henan,China;[3]Department of Tumor Biological Treatment,Third Affiliated Hospital of Soochow University,Changzhou 213003 Jiangsu,China;[4]Department of Oncology,Shanxi Bethune Hospital,Taiyuan 030032 Shanxi,China;[5]Cancer Biotherapy Center,Third Affiliated Hospital of Kunming Medical University(Tumor Hospital of Yunnan Province),Kunming 650118 Yunnan,China;[6]Cancer Center,First Hospital of Jilin University,Changchun 130021 Jilin,China;[7]Laboratory of Immuno-Oncology,Fujian Cancer Hospital&Fujian Medical University Cancer Hospital,Fuzhou 350014 Fujian,China;[8]Department of Immuno-Oncology,Fourth Hospital of Hebei Medical University,Shijiazhuang 050011 Hebei,China高影响力机构 出　　处：《Signal Transduction and Targeted Therapy》索引2020年第5卷第1期,共3页高影响力期刊 基　　金：supported by the National Key Technologies R&D Program of China grant Awards No.2015BAI12B12(to X.R.)and 2018YFC1313400(to J.X.);the National Natural Science Foundation of China grants Awards No.81572913 and 81872487(to L.L.). 摘　　要：Dear Editor,Cytokine-induced killer(CIK)cells have been recognized as a new type of anti-tumor effector cells.CIK cells are a mixture of T lymphocytes.Among them,CD3+/CD56+T cells,which are rare in uncultured peripheral blood,are the main effector cells.CIK cells can proliferate rapidly in vitro,with stronger antitumor activity,broader target tumor spectrum,and lower adverse effect than other reported antitumor effector cells.1 Their ease of production in vitro and antitumor potential have made them suitable candidates for cell therapy regimens in solid and hematopoietic tumor treatments.1,2 Our previous retrospective study showed that the median progression-free survival(PFS)and overall survival(OS)in untreated,advanced non-small-cell lung cancer(NSCLC)patients who received CIK cell immunotherapy plus chemotherapy(13 and 24 months,respectively)were significantly longer than in those who received chemotherapy alone(6 and 10 months,respectively).2 But so far,there is no prospective,multicenter clinical study in lung cancer.Based on our previous study,we designed this randomized,multicenter,open-label trial to further evaluate the clinical efficacy of CIK cell immunotherapy plus chemotherapy in patients with advanced squamous NSCLC(ClinicalTrials.gov number,NCT01631357). 关 键 词：KILLER CHEMOTHERAPY SQUAMOUS
相关文献

参考文献(5)

引证文献(6)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费